Abstract
Shingrix is poorly immunogenic following allogeneic hematopoietic cell transplantation independent of age, CD4, and B-cell recovery.
In hematopoietic cell transplantation recipients with antibody response to the vaccine, varicella zoster virus reactivation risk is not null.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Hematopoietic Stem Cell Transplantation*
-
Herpes Zoster Vaccine*
-
Herpes Zoster*
-
Humans
-
Pilot Projects
-
Vaccines, Synthetic
Substances
-
Herpes Zoster Vaccine
-
Vaccines, Synthetic